Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Conduit Pharmaceuticals ( (CDT) ) has provided an announcement.
On June 3, 2025, Conduit Pharmaceuticals entered a joint development agreement with Manoira Corporation to explore the applicability of its glucokinase activators, AZD1656 and AZD5658, in animal health. This collaboration aims to generate valuable cross-species insights and accelerate Conduit’s human clinical programs while maintaining full ownership of intellectual property. The partnership allows Conduit to tap into the $15 billion animal health market, potentially creating new revenue streams and enhancing shareholder value.
More about Conduit Pharmaceuticals
Conduit Pharmaceuticals is a dynamic, multi-asset clinical stage life science company that focuses on acquiring and funding the development of Phase 2-ready assets. The company employs an integrated platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party license deals after successful clinical trials. Conduit is led by experienced pharmaceutical executives, including Dr. Andrew Regan and Dr. Freda Lewis-Hall.
Average Trading Volume: 328,252
Technical Sentiment Signal: Sell
Current Market Cap: $2.03M
Learn more about CDT stock on TipRanks’ Stock Analysis page.